NasdaqGM:KODBiotechs
A Look At Kodiak Sciences (KOD) Valuation After Zenkuda GLOW2 Phase 3 Success And BLA Plans
Kodiak Sciences (KOD) is back in focus after reporting that its GLOW2 Phase 3 study of Zenkuda in diabetic retinopathy met key efficacy and safety endpoints, supporting a multi-indication, BLA-ready profile.
See our latest analysis for Kodiak Sciences.
The Zenkuda update arrives alongside sharp recent moves in the stock, with a 74.46% 7 day share price return and a 42.24% 30 day share price return. The 1 year total shareholder return is very large, suggesting momentum has picked up sharply...